Legend Biotech (LEGN) Cash & Equivalents (2019 - 2024)
Legend Biotech (LEGN) has disclosed Cash & Equivalents for 6 consecutive years, with $286.7 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Cash & Equivalents fell 77.56% year-over-year to $286.7 million, compared with a TTM value of $286.7 million through Dec 2024, down 77.56%, and an annual FY2024 reading of $286.7 million, down 77.56% over the prior year.
- Cash & Equivalents was $286.7 million for Q4 2024 at Legend Biotech, down from $1.3 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $1.3 billion in Q4 2023 and bottomed at $286.7 million in Q4 2024.
- Average Cash & Equivalents over 5 years is $699.0 million, with a median of $688.9 million recorded in 2021.
- The sharpest move saw Cash & Equivalents soared 446.63% in 2020, then plummeted 77.56% in 2024.
- Year by year, Cash & Equivalents stood at $455.7 million in 2020, then skyrocketed by 51.19% to $688.9 million in 2021, then grew by 14.09% to $786.0 million in 2022, then soared by 62.55% to $1.3 billion in 2023, then tumbled by 77.56% to $286.7 million in 2024.
- Business Quant data shows Cash & Equivalents for LEGN at $286.7 million in Q4 2024, $1.3 billion in Q4 2023, and $786.0 million in Q4 2022.